1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Sweden >
  5. ViroPharma Acquires DuoCort Pharma AB

M&A Deal Summary

ViroPharma Acquires DuoCort Pharma AB

On November 15, 2011, ViroPharma acquired life science company DuoCort Pharma AB for 164M USD

Acquisition Highlights
  • This is ViroPharma’s 3rd transaction in the Life Science sector.
  • This is ViroPharma’s 2nd largest (disclosed) transaction.
  • This is ViroPharma’s 1st transaction in Sweden.

M&A Deal Summary
Date 2011-11-15
Target DuoCort Pharma AB
Sector Life Science
Buyer(s) ViroPharma
Deal Type Add-on Acquisition
Deal Value 164M USD

Target

DuoCort Pharma AB

Helsingborg, Sweden
DuoCort Pharma AB is a drug development company focused on improving glucocorticoid therapy.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

ViroPharma

Exton, Pennsylvania, United States
Category Company
Founded 1994
Sector Life Science
DESCRIPTION

ViroPharma, Inc. is a pharmaceutical company committed to the commercialization, development, and discovery of new antiviral medicines.

DEAL STATS #
Overall 3 of 3
Sector: Life Science M&A 3 of 3
Type: Add-on Acquisition M&A Deals 3 of 3
Country: Sweden M&A 1 of 1
Year: 2011 M&A 1 of 1
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-05-28 Auralis

Halton, United Kingdom

Auralis developed generic pharmaceutical products for niche markets, which were subject to licence or regulatory approval providing barriers to entry to protect margin and revenue.

Buy -
Mergr

Solution for

Product

Company

Legal